パニック障害治療のストラテジー

出版社： 先端医学社
著者：
発行日： 2002-10-31
分野： 臨床医学：内科  >  精神医学
ISBN： 4884070828
電子書籍版： 2002-10-31 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,135 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,567 円(税込)

購入する

商品紹介

本書は、PDをEducation、Guidance、Strategy、Careの5つのパートに分け、それぞれの基本的諸問題から現在の到達点までを専門医が書き下したものである。すべての医療関係者に十分に正確に認知されているとはかぎらないPDの正しい本態の理解と、適切な治療法の実践のために役立つことを願っている。

目次

  • パニック障害治療のストラテジー

    ―　目　次　―

    ■Part1/Education
    I、不安神経症からパニック障害へ
    II、パニック障害の疫学
    III、パニック障害の原因

    ■Part2/Guidance
    I、パニック障害の診断

    ■Part3/Strategy
    I、パニック障害患者への病態説明のポイント
    II、治療選択の基準とその根拠
    III、治療薬剤の種類と症状に応じた選択の根拠
    IV、処方薬剤の服薬中断・減量時の反跳性パニック発作・離脱状態の対策
    V、処方薬剤の副作用発作時の対策
    VI、処方薬剤・他剤との薬物相互作用
    VII、エクスポージャー法のポイント
    VIII、精神療法のポイント

    ■Part4/Practice
    I、パニック障害急性期の治療
    II、安定化・継続期の治療
    III、継続療法のポイント

    ■Part5/Care
    I、慢性の経過をとる患者に対する精神医学的マネージメント
    II、再発防止のための長期的フォローアップ対策
    III、患者への心理社会的アプローチの考え方
    IV、服薬コンプライアンスを高めるための服薬指導

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1/Education

P.10 掲載の参考文献
1) Bellingham D:An Introduction to Greek Mythology, Quintet Publishing Limited, 1989 (安部素子:訳, ギリシャ神話, PARCO出版, 東京, 1993)
 
2) Klerman GL, Hirschfeld MA, Weissman MM et al (eds.):Panic Anxiety and Its Treatment (A Task Force Report of the World Psychiatric Association), APA, Washington DC, pp 3-38 1993. (佐藤啓二, 中根允文:訳パニック性不安とその治療, 先端医学社, 東京, 1995)
 
3) Berrios GE:The History of Mental Symptoms-Descriptive psychopathology since the nineteenth century. Cambridge Univ. Press, Cambridge, pp 263-288, 1996
 
4) 高橋徹:パニック障害-歴史からの展望パニック障害 (貝谷久宣, 不安・抑うつ臨床研究会編), 日本評論社, 東京, pp 23-41, 1998
 
5) 安永浩:不安反応 (不安神経症), 神経症 (井村・懸田・加藤・桜井編), 医学書院, 東京, pp 142-157, 1967
 
6) 西園昌久:神経症:類型, 現代精神医学大系6A神経症と心因反応I (懸田・大熊・島薗・高橋・保崎編), 中山書店, 東京, pp81-236, 1978
 
7) 高橋 徹:神経症と不安障害の概念と歴史的展望 臨床精神医学講座5 神経症性障害・ストレス関連障害 (松下・浅井・牛島・倉知・小山・中根・三好編, 田代・越野責任編), pp 3-13, 1997
 
8) 越野好文:パニック障害と広場恐怖症の位置づけ 臨床精神医学講座5 神経症性障害・ストレス関連障害 (松下・浅井・牛島・倉知・小山・中根・三好編, 田代・越野責任編), pp141-153, 1997
 
9) Lazarus A:The results of behaviour therapy in 126 cases of severe neurosis. Behav Res Ther 1:65-78, 1963
 
10) 中根允文:国際疾病分類-疾病, 傷害及び死因統計分類. the International Statistical Classification of Diseases, Injuries, and Causes of Death (ICD) 臨床精神医学講座別巻1精神科データブック (松下・浅井・牛島・倉知・小山・中根・三好編, 浅井・中根責任編), pp 3-37, 2001
 
11) 野崎昭子, 大野 裕:Diagnostic and Statistical Manual of Mental disorders (DSM) 臨床精神医学講座 別巻1 精神科データブック (松下・浅井・牛島・倉知・小山・中根・三好編, 浅井・中根責任編), pp 39-106, 2001
 
12) World Health Organization Mental Disorders:Glossary and guide to their classification in accordance with the Ninth Revision of the International Classification of Diseases. WHO, Geneva, 1978 (厚生省大臣官房統計情報部/編 疾病,傷害及び死因統計分類提要 昭和54年版, 第2巻, 厚生統計協会, 東京, 1978)
 
13) 中根允文:ICD-10からみたDSM-IV. 臨床精神医学25:301-306, 1996
 
14) Klerman GL:感情 (気分) 障害と不安障害-ICD-10開発に向けての考察. 精神科国際診断の展望 (加藤・是恒・丸太:訳), 中央洋書出版部, 東京, pp 176-185, 1991 (Mezzich JE, von Cranach M eds. International Classification in Psychiatry, Unity and Diversity, Cambridge Univ. Press, 1988 )
 
15) World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders,Diagnostic criteria for research, WHO,Geneva,1993(中根允文,岡崎祐士,藤原 妙子:訳 ICD-10精神および行動の障害 DCR研究用診断基準,医学書院,東京,1994)
 
16) Feighner JP,Robins E,Guze SB et al:Diagnostic criteria for use in psychiatric research, Arch Gen Psychiatry 26:57-63,1972
PubMed
17) Spitzer RL,Endicott J ,Robins E:Clinical criteria for psychiatric diagnosis and DSM-III, Am J Psychiatry 132:1187-1192,1975
PubMed
18) American Psychiatric Association Diagnostic and Statistic Manual of Mental Disorders (Third Edition) ,APA, Washington DC,pp 371-398 (Appendix C:Annotated Comparative Listing of DSM-Uand DSM-III),1980(高橋三郎,花田耕一, 藤縄昭:訳 DSM-III精神障害の分類と診断の手引,医学書院,東京,1982)
 
19) Klein DF,Zitrin CM ,Woerner MG:Antidepressants,anxiety,panic and phobia In Psychopharmacology:A Generation of Progress (Lipton MA,DiMascio A,Killam KF eds,), New York,Raven Press,pp 1401-1410,1978
 
20) Zitrin CM,Klein DF,Woerner MG:Behavior therapy,supportive psychotherapy,imipramine and phobias, Arch Gen Psychiatry 35:307-316,1978
PubMed
21) American Psychiatric Association Diagnostic and Statistic Manual of Mental Disorders (Third Revised Edition),APA,Washington DC,1987(高橋三郎:訳 DSM-III R精神疾患の診断・統計マニュアル,医学書院,東京,1988)
 
22) American Psychiatric Association Diagnostic and Statistic Manual of Mental Disorders (Fourth Edition),APA,Washington DC,1995 (高橋三郎,大野 裕,染矢俊幸:訳 DSM-IV 精神疾患の診断・統計マニュアル,医学書院,東京,1996,)
 
23) 藤井 薫:パニック・ディスオーダーについて, 精神医学レビュー3(パニックディスオーダー):5-14,1993
 
24) Klein DF,Fink M:Psychiatric reaction patterns to imipramin, Am J Psychiatry 119:432-438,1962,
PubMed
25) Klein DF:Delineation of two drug-responsive anxiety syndromes, Psychopharmacologia 5:397-408,1964
PubMed
26) Klein DF:Importance of psychiatric diagnosis in prediction of clinical drug effects, Arch Gen Psychiatry 16:118-126,1967
PubMed
27) Freud S:Uber die Berechtigung von der Neurasthenie einen bestimmten symptomen komplex als "Angstneurose" abzuttrennen (1894), The Standard Edition of the Complete Psychoanalytic Works of Sigmund Freud,vol 3,Hogarth Press,London,1962, (加藤正明:訳「不安神経症」という特定症状を神経衰弱から分離する理由について,『フロイト選集10』,日本教文社,東京,1969
 
28) 懸田克躬,加藤正明,下坂幸三ほか:神経症類型論の歴史・諸見地およびその問題点, 神経症 (井村・懸田・加藤・桜井編) ,医学書院,東京,pp 127-141,1967
 
29) 森田正馬:神経質ノ本態及療法(1928) ,森田正馬全集,第2巻,白揚社,東京,1974
 
30) 長岡興樹:不安神経症の臨床的研究(第一報) 病前性格-臨床統計的観点から, 九州神経精神医学32:278-297,1986
 
31) 長岡興樹:不安神経症の臨床的研究(第一二報) 発症状況・発症契機と転帰-臨床統計的観点から, 九州神経精神医学32:298-320,1986
 
32) 高橋 徹:急性不安発作で始まった不安神経症の経過について, 精神医学23:1225-1232,1981
 
33) 井野恵三,高橋三郎,山根秀夫ほか:DSM-III 診断基準の適応とその問題点,6不安病, 臨床精神医学10:349-356,1981
 
34) 山下 格:わが国における神経症の診断とDSM-III 臨床精神医学11:205-212,1982
 
35) 花田耕一,高橋三郎:わが国におけるDSM-III 臨床試行-7大学附属病院における精神科医間の診断一致度-, 臨床精神医学11:171-181,1982
 
36) Satoh K,Fujii I:Current views on panic disorder and its management in Japan:a national survey. Jpn J Psuchiatry Neuro 46:45-53,1992
 
37) 塩入俊樹,村下 淳,高橋三郎:恐慌性障害におけるDSM-IIIR診断とICD-10DCR診断との比較について, PANIC GRAND ROUND 6:55-69,1992
 
38) 花田耕一:パニックディスオーダーの診断基準をめぐって, 精神医学レビュー3(パニックディスオーダー):15-21, 1993
 
39) 塩入俊樹, 村下 淳, 加藤忠史ほか:恐慌性障害の症例研究. PANIC GRAND ROUND 95:62-80, 1996.
 
40) 佐藤啓二, 石倉佐和子:パニック障害について, パニック障害の心理的治療法-理論と実践-(佐藤啓二・高橋 徹編), ブレーン出版, 東京, pp 11-42, 1996
 
41) 山下 格:岩崎徹也, 小口 徹ほか:神経症圏障害の診断基準試案. 精神医学31:345-352, 1989
 
42) 山下 格:神経症概念-最近の動向. 現代精神医学大系年刊版89-A (懸田・島薗・大熊・高橋・保崎編), pp 157-174, 中山書店, 東京 1990
 
43) Pitts FN Jr, McClure JN Jr:Lactate metabolism in anxiety neurosis. N Engl J Med 277:1329-1336, 1967
PubMed
44) Mezzich JE, Usutun TB, Cox JL:(Symposium Chairs) Symposium International Classification and Diagnosis organized WHO and WPA (Abstract), London, UK, 12-13 July, 2001
 
P.17 掲載の参考文献
1) Wittchen HU, Essau CA:Epidemiology of panic disorder:progress and unresolved issues. J Psychiatr Res 27:47-68, 1993
PubMed
2) Eaton WW, Regier DA, Locke BZ et al:The Epidemiologic Catchment Area Program of the National Institute of Mental Health. Public Health Rep 96:319-325, 1981
PubMed
3) Eaton WW, Kessler RC, Wittchen HU et al:Panic and panic disorder in the United States. Am J Psychiatry 151:413-420, 1994
PubMed
4) Aoki Y, Fujihara S, Kitamura T:Panic attacks and panic disorder in Japanese non-patient population:epidemiology and psychosocial correlates. J Affect Disord 32:51-59, 1994
PubMed
5) Eaton WW, Kramer M, Anthony JC et al:The incidence of specific DIS/DSM-III mental disorders:data from the NIMH Epidemiologic Catchment Area Program. Acta Psychiatr Scand 79:163-178, 1989
PubMed
6) Von Korff MR, Eaton WW, Keyl PM:The epidemiology of panic attacks and panic disorder. Results of three community surveys. Am J Epidemiol 122:970-981, 1985
PubMed
7) Katerndahl DA, Realini JP:Lifetime prevalence of panic states. Am J Psychiatry 150:246-249, 1993
PubMed
8) Lindal E, Stefansson JG:The lifetime prevalence of anxiety disorders in Iceland as estimated by the US National Institute of Mental Health Diagnostic Interview Schedule. Acta Psychiatr Scand 88:29-34, 1993
PubMed
9) Flint AJ:Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 151:640-649, 1994
PubMed
10) Regier DA, Boyd JH, Burke JD Jr et al:Onemonth prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 45:977-986, 1988
PubMed
11) Hwu HG, Yeh EK, Chang LY:Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule. Acta Psychiatr Scand 79:136-147, 1989
PubMed
12) Lepine Jp, Pelissolo A:Epidemiology comorbidity and genetics of panic disorder.ed. by Nutt DJ, Ballenger JC, Lepine Jp, Martin Dunitz, London, 1999, pp. 9-24
 
13) Breslau N, Klein DF:Smoking and panic attacks:an epidemiologic investigation. Arch Gen Psychiatry 56:1141-1147, 1999
PubMed
14) Weissman MM, Merikangas KR, John K et al:Family-genetic studies of psychiatric disorders. Developing technology. Arch Gen Psychiatry 43:1104-1116, 1986
PubMed
15) Moran C, Andrews G:The familial occurrence of agoraphobia. Br J Psychiatry 146:262-267, 1985
PubMed
16) Vieland VJ, Hodge SE, Lish JD et al:Segregation analysis of panic disorder. Psychiat Genet 3:63-71, 1993
 
17) 稲田泰之:精神疾患の遺伝因解明の現状と展望-パニック障害-. 臨床精神医学講座S11精神疾患の遺伝, 中山書店, 東京, pp. 273-280, 2000
 
18) Crowe RR, Noyes R Jr, Samuelson S et al:Closelinkage between panic disorder and alphahaptoglobin excluded in 10 families. Arch Gen Psychiatry 47:377-380, 1990
PubMed
19) Noyes RJ, Clancy J, Crowe RR et al:The familial prevalence of anxiety neurosis. Arch Gen Psychiatry 35:1057-1074, 1978
 
20) Crowe RR, Noyes R Jr, Pauls DL et al:A family study of panic disorder. Arch Gen Psychiaty 40:1065-1069, 1983
 
21) Hopper JL, Judd FK, Derrick PL et al:A family study of panic disorder. Genet Epidemiol 4:33-41, 1987
 
22) Knowles JA, Weissman MM:Panic disorder and agoraphobia, in American Psychiatric Press Review of Psychiatry, vol14.ed. by Oldham JM, Riba MJ, American Psychiatric Press, Washington DC, 1995, pp. 383-404
 
23) Noyes R Jr, Crowe RR, Harris EL et al:Relationship between panic disorder and agor aphobia. A family study. Arch Gen Psychiatry 43:227-232, 1986
 
24) Harris EL, Noyes R Jr, Crowe RR et al:Family study of agoraphobia. Report of a pilot study. Arch Gen Psychiatry 40:1061-1064, 1983
 
25) Goldstein RB, Weissman MM, Adams PB et al:Psychiatric disorders in relatives of probands with panic disorder and/or major depression. Arch Gen Psychiatry 51:383-394, 1994
PubMed
26) Goldstein RB, Wickramaratne PJ, Horwath E et al:Familial aggregation and phenomenology of 'early'-onset (at or before age 20 years) panic disorder. Arch Gen Psychiatry 54:271-278, 1997
PubMed
27) Torgersen S:Genetic factors in anxiety disorders. Arch Gen Psychiatry 40:1085-1089, 1983
PubMed
28) Kendler KS, Neale MC, Kessler R et al:Generalized anxiety disorder in women. A population based twin study. Arch Gen Psychiatry 49:267-272, 1992
PubMed
29) Skre I, Onstad S, Torgersen S et al:A twin study of DSM-III-R anxiety disorders. Acta Psychiat Scand 88:85-92, 1993
PubMed
30) Perna G, Caldirola D, Arancio C et al:Panic attacks:a twin study. Psychiatry Res 66:69-71, 1997
PubMed
31) Weissman MM, Bland RC, Canino GJ et al:The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54:305-309, 1997
PubMed
32) 竹内龍雄, 林竜介, 富山學人ほか:不安神経症の慢性期病像について. 精神医学30:105-107, 1988
 
33) Breier A, Charney DS, Heninger GR:Major depression in patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:1129-1135, 1984
PubMed
34) Kendler KS, Walters EE, Neale MC et al:The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobic, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen 52:374-383, 1995
PubMed
35) Johnson J, Weissman MM, Klerman GL:Panic disorder, comorbidity, and suicide attempts. Arch Gen Psychiatry 47:805-808, 1990
PubMed
36) Beck AT, Steer RA, Sanderson WC et al:Panic disorder and suicidal ideation and behavior discrepant findings in psychiatric outpatients. Am J Psychiatry 148:1195-1199, 1991
PubMed
37) Friedman S, Jones JC, Chernen L et al:Suicidal ideation and suicide attempts among patients with panic disorder:a survey of two outpatient clinics. Am J Psychiatry 149 680-685, 1992
PubMed
38) Faravelli C, Guerrini DB, Sessarego A et al:Personality features of patients with panic anxiety. New Trends Exper Clin Psychiatry 3:13-23, 1987
 
39) Bienvenu OJ, Nestadt G, Samuels JF et al:Phobic, panic, and major depressive disorders and the five-factor model of personality. J Nerv Ment Dis 189:154-161, 2001
PubMed
P.32 掲載の参考文献
1) Abelson JL, Weg JG, Nesse RM et al:Persistent respiratory irregularity in patients with panic disorder. Biol Psychiatry 49:588-595, 2001
PubMed
2) 藍沢鎮雄, 星野良一, 竹内龍雄ほか:不安神経症者の性格特徴について. 精神医学27:287-293, 1985
 
3) Akiyoshi J Moriyama T, Isogawa K et al:CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder. J Neurochem 66:1610-1616, 1996
 
4) Akiyoshi J, Isogawa K, Tsutsumi T et al:Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia. Biol Psychiatry 42:151-154, 1997
PubMed
5) Akiyoshi J, Yamauchi C, Furuta M et al:Relationship between SCL-90, Maudsley Personality Inventory and CCK4-induced intracellular calcium response in T cells. Psychiatry Res 81:381-386, 1998
 
6) 穐吉條太郎:認知機能異常モデル. こころの臨床 a・la・carte第17巻増刊号:170-173, 1998
 
7) 穐吉條太郎:パニック障害の精神薬理遺伝学的研究. 日本神経精神薬理学雑誌19:93-99, 1999
 
8) 穐吉條太郎:不安とコレシストキニン. Clin Neurosci 17:44-47, 1999
 
9) 穐吉條太郎:不安障害の脳科学. 臨床科学35:96-101, 1999
 
10) Anisman H, Zaharia MD, Meaney MJ et al:Do early-life events permanently alter behavioral and hormonal responses to stressors? Int J Dev Neuroscience 16:149-164, 1998
 
11) Argyle N, Roth M:The phenomenological study of 90 patients with panic disorder, Part II. Psychiartr Dev 3:187-209, 1989
PubMed
12) Barlow DH:Cognitive-behavioral therapy for panic disorder:current status. J Clin Psychiatry 58 (Suppl 2):32-36, 1997
 
13) Barlow DH, Gorman JM, Shear MK et al:Cognitive-behavioral therapy, imipramine, or their combination for panic disorder:A randomized controlled trial. JAMA 283:2529-2536, 2000
 
14) Battaglia M, Bertella S, Ogliari A et al:Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry 58:114-119, 2001
PubMed
15) Birbaumer N, Grodd W, Diedrich O et al:fMRI reveals amygdala activation to human faces in social phobics. Neuroreport 9:1223-1226, 1998
PubMed
16) Bremner JD, Innis RB, White T et al:SPECT [I-123] iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 47:96-106, 2000
PubMed
17) Britton KT, Akwa Y, Spina MG et al:Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides 21:37-44, 2000
 
18) Butler J, O'Halloran A, Leonard BE:The Galway Study of Panic Disorder.II:Changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder. J Affect Disord 26:89-99, 1992
PubMed
19) Caldji C, Tannenbaum B, Sharma S et al:Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat. Proc Natl Acad Sci USA 95:5335-5340, 1998
PubMed
20) Cameron O, Huang G, Frey K et al:Brain benzodiazepine binding sites in panic disorder. Neuroimage 11 (5, pt2):S185, 2000
 
21) Cavallini MC, Perna G, Caldirola D et al:A segregation study of panic disorder in families of panic patients responsive to the 35% CO2 challenge. Biol Pyschiatry 46:815-820, 1999
 
22) Charney DS, Heninger GR, Breier A:Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751-763, 1984
PubMed
23) Charney DS, Innis RB, Duman RS et al:Platelet alpha-2-receptor binding and adenylate cyclase activity in panic disorder. Psychopharmacology 98:102-107, 1989
PubMed
24) Cohen LS, Sichel DA, Faraone SV et al:Course of panic disorder during Pregnancy and the puerperium:a preliminary study. Biol Psychiatry 39:950-954, 1996
PubMed
25) Coryell W, Fyer A, Pine D et al:Aberrant respiratory sensitivity to CO2 as a trait of familial panic disorder. Biol Psychiatry 49:582-587, 2001
PubMed
26) Cratty MS, Birkle DL:N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons. Peptides 20:93-100, 1999
PubMed
27) Crestani F, Benke D, Reyes G et al:Impairment of GABA-A receptor function by subunit genetargeting in mice results in neophobia. Soc Neurosci Abst 372:2, 1996
 
28) Crowe RR, Noyes R, Pauls DL et al:A family study of panic disorder. Arch Gen Psychiatry 40:1065-1069, 1983
PubMed
29) Crowe RR, Noyes R Jr, Wilson AF et al:A linkage study of panic disorder. Arch Gen Psychiatry 44:933-937, 1987
PubMed
30) Crowe RR, Noyes R Jr, Persico AM:Pro-opiomelanocortin (POMC) gene excluded as a cause of panic disorder in a large family. J Affect Disord 12:23-27, 1987
 
31) Crowe RR, Noyes R Jr, Samuelson S et al:Close linkage between panic disorder and alpha-haptoglobin excluded in 10 families. Arch Gen Psychiatry 47:377-380, 1990
PubMed
32) Dager SR, Friedman SD, Heide A et al:Two-dimensional proton echo-planar spectroscopic imaging of brain metabolic changes during lactate-induced panic. Arch Gen Psychiatry 56:70-77, 1999
PubMed
33) Crowe RR, Wang Z, Noyes R Jr et al:Candidate gene study of eight GABAA receptor subunits in panic disorder. Am J Psychiatry 154:1096-1100, 1997
PubMed
34) Dager SR, Strauss WL, Marro KI et al:Proton magnetlc resonance spectroscopy lnvestigation of hyperventilation in subjects with panic disorder and comparison subjects. Am J Psychiatry 152:666-672, 1995
 
35) Dantendorfer K, Prayer D, Kramer J et al:High frequency of EEG and MRI brain abnormalities in panic disorder. Psychistr Res 68:41-53, 1996
 
36) Davis M, Rainnie D, Cassell M:Neurotrans mission in the rat amygdala related to fear and anxiety. Trends Neurosci 17:208-214, 1994
 
37) Deckert J, Catalano M, Heils A et al:Functionalpromoter polymorphism of the human serotonin transporter:lack of association with panic disorder. Psychiatr Genet 7:45-47, 1997
PubMed
38) Deckert J, Nothen MM, Franke P et al:Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol Psychiatry 3:81-85, 1998
 
39) Deckert J:The adenosine A (2A) receptor knockout mouse:a model for anxiety? Int J Neuropsychopharmacol 1:187-190, 1998
 
40) Deckert J, Catalano M, Syagailo YV et al:Excessof high activity monoamine oxidase A gene promoter alleles in female patients with phobic disorder. Hum Mol Genet 8:621-624, 1999
 
41) Faravelli C, Webb T, Ambonetti A et al:Prevalence of traumatic early life events in 31 agoraphobic patients with panic attacks. Am J Psychiatry 142:1493-1494, 1985
PubMed
42) Faravelli C, Pallanti S:Recent life events and panic disorder. A J Psychiatry 146:622-626, 1989
 
43) Francis DD, Meaney MJ:Maternal care and the development of stress responses. Curr Opin Neurobiol 9:128-134, 1999
PubMed
44) Fredrikson M, Wik G, Fisher H et al:Affective and attentive neural networks in humans:a PET study of Pavlovian conditioning. Neuro-report 7:97-101, 1995
 
45) 古田真理子, 工藤貴代美, 山田久美子ほか:パニック障害における治療抵抗性の予測因子について. 精神医学41:79-83, 1999
 
46) Fyer AJ, Mannuzza S, Chapman TF et al:Specificity in familial aggregation of panic disorders. Arch Gen Psychiatry 52:564-573, 1995
PubMed
47) Fyer AJ, Mannuzza S, Chapman TF et al:Panic disorder and social phobia:effects of comorbidity on familial transmission. Anxiety 2:173-178, 1996
PubMed
48) Garvey MJ, Crowe RR, Wang Z:An association of NAG levels and a mutation of the CCK gene in panic disorder patients. Psychiatry Res 80:149-153, 1998
 
49) Goddard AW, Mason GF, Almai A et al:Reductions in occipital cortex GABA levels inpanic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58:556-561, 2001
PubMed
50) Goldstein RB, Weissman MM, Adams PB et al:Psychiatric disorders in relatives of probands with panic disorder and/or major depression. Arch Gen Psychiatry 51:383-394, 1994
PubMed
51) Goldstein RB, Wickramaratne PJ, Horwath E et al:Familial aggregation and phenomenology of 'Early' Lonset (at or before age 20 years) panic disorder. Arch Gen Psychiatry 54:271-278, 1997
PubMed
52) Gorman JM, Kent JM, Sullivan GM et al:Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157:493-505, 2000
PubMed
53) Griebel G:Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 82:1-61, 1999
 
54) Hamilton SP, Heiman GA, Haghighi F et al:Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder. Psychiatr Genet 9:1-6, 1999
PubMed
55) Hamilton SP, Slager SL, Helleby L et al:No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. Mol Psychiatry 6:59-65, 2001
PubMed
56) Hansen TV, Rehfeld JF, Nielsen FC:Function of the C-36 to T polymorphism in the human cholecystokinin gene promoter. Mol Pschiatry 5:443-447, 2000
 
57) Hattori E, Ebihara M, Yamada K et al:Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia. Mol Psychiatry 6:465-470, 2001
 
58) 林竜介, 竹内龍雄:パニック障害患者の病前性格特徴について. Upjohn Symposium 6:Panic Grand Round:19-23, 1993
 
59) Hikichi T, Akiyoshi J, Yamamoto Y et al:Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry 33:189-193, 2000
PubMed
60) Horesh N, Amir M, Kedem P et al:Life events in childhood, adolescence and adulthood and therelationship to panic disorder. Acta Psychiatr Scand 96:373-378, 1997
 
61) 堀之内由紀子, 穐吉條太郎:不安障害の遺伝子研究から見た新たな治療薬の可能性. 臨床精神薬理 4:213-222, 2001
 
62) Horwath E, Wolk SI, Goldstein RB et al:Is the comorbidity between social phobia and panic disorder due to familial cotransmission or other factors? Arch Gen Psychiatry 52:574-582, 1995
PubMed
63) Inada Y, Yoneda H, Nonomura Y et al:An association study between the A1 and A2a adenosine receptor genes and panic disorder. Am J Med Genet 81:523, 1998
 
64) 稲田泰之, 康純, 堺潤ほか:パニック障害とセロトニン2C受容体遺伝子多型との相関研究. 精神薬療基金研究年報 31:106-109, 1999
 
65) Ishiguro H, Arinami T, Yamada K et al:An association study between a transcriptional polymorphism in the serotonin transporter gene and panic disorder in a Japanese population. Psychiatry Clin Neurosci 51:333-335, 1997
 
66) Isogawa K, Akiyoshi J, Hikichi T et al:Effect of corticotropin releasing factor receptor lantagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo. Neuropeptides 34:234-239, 2000
 
67) Javanmard M, Shlik J, Kennedy SH et al:Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans:a comparison of two time points. Biol Psychiatry 45:872-882, 1999
PubMed
68) Jenck F, Ouagazzal AM, Pauly-Evers M et al:OrphaninFQ:role in behavioral fear responses and vulnerability to stress? Psychiatry 5:572-574, 2000
PubMed
69) Kato T, Wang ZW, Zoega T et al:Missense mutation of the cholecystokinin B receptor gene:lack of association with panic disorder. Am J Med Genet 67:401-405, 1996
PubMed
70) 加藤忠史:気分障害. 最新精神医学 2:423-429, 1997
 
71) Kendler KS, Heath A, Martin NG et al:Symptoms of anxiety and depression in a volunteer twin population:The etiologic role of genetic and environmental factors. Arch Gen Psychiatry 43:213-221, 1986
 
72) Kendler KS, Neale MC, Kessler RC et al:Panic disorder in women:a population-based twin study. Psychol Med 23:397-406, 1993
PubMed
73) Kendler KS, Walters EE, Neale MC et al:The structure of the genetic and environmental risk factors for six major psychiatric disorders in women:Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alchoholism. Arch Gen Psychiatry 52:374-383, 1995
 
74) Kennedy JL, Bradwejn J, Koszycki D et al:Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatr 4:284-285, 1999
 
75) Kerr TA, Schapira K, Roth M et al:The relationship between the Maudsley Personality Inventory and the course of affective disorders. Br J Psychiatry 116:11-19, 1970
PubMed
76) Klein D:Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5:397-408, 1964
PubMed
77) Klein DF:Anxiety reconceptualized. Compr Psychiatry 21:411-427, 1980
PubMed
78) Klein DF:False suffocation alarms, spontaneous panics, and related conditions:An integrative hypothesis. Arch Gen Psychiatry 50:306-317, 1993
 
79) Klein DF:Panic and phobic anxiety:pheno-types, endophenotypes, and genotypes. Am J Psychiatry 155:1147-1149, 1998
 
80) Kopin AS, McBride EW, Gordon MC et al:Inter-and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy. Proc Natl Acad Sci USA 94:11043-11048, 1997
PubMed
81) Krystal JH, D:Souza DC, Sanacora G et al:Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorder. Med Clin North Am 85:559-577, 2001
PubMed
82) Kushner MG, Thomas AM, Bartels KM et al:Panic disorder history in the families of patients with angiographically normal coronary arteries. Am J Psychiatry 149:1563-1567, 1992
PubMed
83) LaBar KS, Gatenby JC, Gore JC et al:Human amygdala activation during conditioned fear acquisition and extinction:a mixed-trial fMRI study. Neuron 20:937-945, 1998
PubMed
84) Lesch KP, Bengel D, Heils A et al:Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531, 1996
PubMed
85) Maier W, Lichtermann D, Minges et al:A controlled family study in panic disorder. J Psychiatr Res 27 (Suppl 1):79-87, 1993
 
86) Malizia AL, Cunningham VJ, Bell CJ et al:Decreased brain GABA (A)-benzodiazepine receptor binding in panic disorder:preliminary results from a quantitative PET study. Arch Gen Psychiatry 55:715-720, 1998
 
87) Manfro GG, Otto MW, McArdle ET et al:Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord 41:135-139, 1996
PubMed
88) Mannuzza S, Chapman TF, Klein DF et al:Familial transmission of panic disorder:effect of major depression comorbidity. Anxiety 1:180 185, 1994/1995
 
89) Martin NG, Jardine R, Andrews G et al:Anxiety disorders and neuroticism:are these genetic factors specific to panic? Acta Psychiatr Scand 77:698-706, 1988
PubMed
90) Mendlewicz J, Papdimitriou G, Wilmotte J:Family study of panic disorder:Comparison with generalized anxiety disorder, major depression and normal subjects. Psychiatr Genet 3:73-78, 1993
 
91) Meyer JH, Swinson R, Kennedy SH et al:Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. Psychiatry Res 98:133-143, 2000
PubMed
92) Mutchler K, Crowe RR, Noyes R Jr et al:Exclusion of the tyrosine hydroxylase gene in 14 panic disorder pedigrees. Am J Psychiatry 147:1367-1369, 1990
PubMed
93) Nakamura M, Ueno S, Sano A et al:Polymorphisms of the human homologue of the Drosophila white gene are associated with mood and panic disorders. Mol Psychiatry 4:155-162, 1999
 
94) Noyes R Jr, Clancy J, Crowe R et al:The familial prevalence of anxiety neurosis. Arch Gen Psychiatry 35:1057-1074, 1978
PubMed
95) Noyes R Jr, Crowe RR, Harris EL et al:Relationship between panic disorder and agoraphobia:A family study. Arch Gen Psychiatry 43:227-232, 1986
PubMed
96) Nutt DJ, Glue P, Lawson C et al:Flumazenil provocation of panic attacks:Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 47:917-925, 1990
PubMed
97) Nutt DJ, Forshall S, Bell C et al:Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 9 (Suppl 3):S81-86, 1999
 
98) 大原浩市:精神分裂病. 最新精神医学 2:417-421, 1997
 
99) Ohara K, Suzuki Y, Ochiai M et al:Polymorphism in the promoter region of the alpha (2A)-adrenergic receptor gene and panic disorders. Psychiatry Res 93:79-82, 2000
PubMed
100) 尾中達史, 八木欽治:情動ストレスと神経内分泌反応. Clin Neurosci 17:752-755, 1999
 
101) 大曽根彰:パニック障害と分離不安. 精神医学 42:953-961, 2000
 
102) Pauls DL, Bucher KD, Crowe RR et al:Agenetic study of panic disorder pedigrees. Am J Hum Genet 32:639-644, 1980
 
103) Perna G, Caldirola D, Arancio C et al:Panic attacks:a twin study. Psychiatry Res 66:69-71, 1997
PubMed
104) Phillips RG, LeDoux JE:Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106:274-285, 1992
PubMed
105) Ramboz S, Oosting R, Amara DA et al:Serotonin receptor 1A knockout:an animal model of anxiety-related disorder. Proc Natl Acad Sci USA 95:14476-14481, 1998
PubMed
106) Rapee RM, Litwin EM, Barlow DH:Impact of life events on subjects with panic disorder and on comparison subjects. Am J Psychiatry 147:640-644, 1990
PubMed
107) Reich J, Noyes R Jr, Troughton E:Dependent personality disorder associated with phobic avoidance in patients with panic disorder. Am J Psychiatry 144:323-326, 1987
PubMed
108) Roth M:The panic-agoraphobic syndrome:a paradigm of the anxiety group of disorders and its implications for psychiatric practice and theory. Am J Psychiatry 153:111-124, 1996
PubMed
109) Roy-Byrne PP, Geraci M, Uhde TW:Life events and the onset of panic disorder. Am J Psychiatry 143:1424-1427, 1986
PubMed
110) Roy-Byrne PP. Cowley DS, Greenblatt DJ et al:Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 47:534-538, 1990
PubMed
111) Schmidt SM, Zoega T, Crowe RR:Excluding linkage between panic disorder and the gamma-aminobutyric acid beta 1 receptor locus in five Icelandic pedigrees. Acta Psychiatr Scand 88:225-228, 1993
PubMed
112) Schoepp DD, Jane DE, Monn JA:Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharma-cology 38:1431-1476, 1999
 
113) Shear MK:Factors in the etiology and pathogenesis of panic disorder:revisiting the attachment-separation paradigm. Am J Psychiatry 153:125-136, 1996
PubMed
114) Shekhar A, Keim SR, Simon JR et al:Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav 55:249-256, 1996
PubMed
115) Silove D, Manicavasagar V, O'onnell D et al:The development of the Separation Anxiety Symptom Inventory (SASI) . Aust N Z J Psychiatry 27:477-488, 1993
 
116) Skre I, Onstad S, Torgersen S et al:Atwin study of DSM-III-Ranxiety disorders. Acta Psychiatr Scand 88:85-92, 1993
 
117) Smoller JW, Tsuang MT:Panic and phobic anxiety:defining Phenotypes for genetic studies. Am J Psychiatry 155:1152-1162, 1998
PubMed
118) Smith LC, Friedman S, Nevid J:Clinical and sociocultural differences in African American and European American patients with panic disorder and agoraphobia. J Nerv Ment Dis 187:550-560, 1999
 
119)Stein DJ, Stahl S:Serotonin and anxiety:current models. Int Clin Psychopharmacol 15 (Suppl 2):S1-S6, 2000
 
120) Stein MB, Jang KL, Livesley WJ:Heritability of anxiety sensitivity:a twin study. Am J psychiatry 156:246-251, 1999
PubMed
121) Stein MB, Walker JR, Anderson G et al:Childhood physical and sexual abuse in patients with anxiety disorders and in a community sample. Am J Psychiatry 153:275-277, 1996
 
122) Torgersen S:Genetic factors in anxiety disorders. Arch Gen Psychiatry 40:1085-1089, 1983
PubMed
123) van Beek N, Griez E:Reactivity to a 35% CO2 challenge in healthy first-degree relatives of patients with panic disorder. Biol Psychiatry 47:830-835, 2000
PubMed
124) van den Heuvel OA, van de Wetering BJ, Veltman DJ et al:Genetic studies of panic disorder:a review. J Clin Psychiatry 61:756-766, 2000
PubMed
125) Vieland VJ, Hodge SE, Lish JD et al:Segregation analysis of panic disorder. Psych Genetics 3:63-71, 1993
 
126) Vieland VJ, Goodman DW, Chapman T et al:New segregation analysis of panic disorder. Am J Med Genet 67:147-153, 1996
PubMed
127) Vythilingam M, Anderson ER, Goddard A et al:Temporal lobe volume in panic disorder-a quantitative magnetic resonance imaging study. Psychiatr Res 99:75-82, 2000
 
128) Wang ZW, Crowe RR, Noyes R Jr:Adrenergic receptor genes as candidate genes for panic disorder:a linkage study, Am J Psychiatry 149:470-474, 1992
PubMed
129) Weissman MM, Wickramaratne P, Adams PB et al:The relationship between panic disorder and major depression:A new family study. Arch Gen Psychiatry 50:767-780, 1993
PubMed
130) Westh-Hansen S, Rasmussen P, Hastrup S et al:Decreased agonist sensitivity of human GABA(A) receptors by amino acid variant, isoleucine to valine, in the alpha 1 subunit. Euro J Pharmacology 329:253-257, 1997
 
131) Wiedemann K, Jahn H, Yassouridis A et al:Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks:preliminary findings. Arch Gen Psychiatry 58:371-377, 2001
PubMed
132) Winsner KL, Peindl KS, Hanusa BH:Effects of childbearing on the natural history of panic disorder with comorbid mood disorder. J Affect Dis 41:173-180, 1996
 
133) 山田久美子, 藤井 薫, 穐吉條太郎:パニック障害の対処行動:転帰の予測因子. 精神医学40:607-612, 1998
 
134) Yamamoto Y, Akiyoshi J, Kiyota A et al:Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor. Brain Res Bull 53:789-792, 2000
PubMed

Part 2/Guidance

P.51 掲載の参考文献
1) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, Third Edition. American Psychiatric Association, Washington, DC, 1980
 
2) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised. American Psychiatric Association, Washington, DC, 1987
 
3) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association, Washington, DC, pp393-403, 1994
 
4) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association, Washington, DC, 1994-高橋三郎, 大野 裕, 染矢俊幸 (訳):DSM-IV精神疾患の分類と診断の手引き. pp161-162, 医学書院, 東京 (1995)
 
5) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association, Washington, DC, pp698-699, 1994 (高橋 三郎, 大野 裕, 染矢俊幸 (訳):DSM-IV精神疾患の診断・統計マニュアル. 医学書院, 東京 (1996), pp698-699)
 
6) Bass C:Hyperventilation syndrome:a chimera? J Psychosom Res 42:421-426, 1997
 
7) Beitman BD, Kushner M, Lamberti JW et al:Panic disorder without fear in patients with angiographically normal coronary arteries. J Nerv Ment Dis 178:307-312, 1990
PubMed
8) Fyer AJ, Mannuzza S, Coplan JD:Panic disorder and agoraphobia. in Kaplan HI, Sadock BJ:Comprehensive Textbook of Psychiatry, 6th ed., Williams and Wilkins, Baltimore, pp1191-1204, 1995
 
9) Gorman JM, Askanazi J, Liebowitz MR et al:Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 141:857-861, 1984
 
10) Hauri PJ, Friedman M, Ravaris CL:Sleep in patients with spontaneous panic attacks. Sleep 12:323-337, 1989
PubMed
11) Hornsveld HK, Garssen B, Dop MJ et al:Double-blind placebo-controlled study of the hyper ventilation provocation test and the validity of the hyperventilation syndrome. Lancet 348:154-158, 1996
 
12) Horwath E, Lish JD, Johnson J et al:Agoraphobia without panic:clinical reappraisal of an epidemiologic finding. Am J Psychiatry 150:1496-1501, 1993
PubMed
13) Leckman JF, Weissman MM, Merikangas KR et al:Panic disorder and major depression. Increased risk of depression, alcoholism, panic, and phobic disorders in families of depressed probands with panic disorder. Arch Gen Psychiatry 40:1055-1060, 1983
PubMed
14) Mellman TA, Uhde TW:Sleep panic attacks:new clinical findings and theoretical implications. Am J Psychiatry 146:1204-1207, 1989
PubMed
15) Spitzer RL, Endicott J, Robins E et al:Preliminary report of the reliability of Research Diagnostic Criteria applied to psychiatric case records. edited by Sudilovsky A, Gershon S, Beer B:Predicability in psychopharmachology:Preclinical and clinical correlations. New York, Raven Press, pp 1-47, 1975d
 
16) 竹内龍雄:疫学・経過・予後 (パニック障害) . 松下正明総編集:臨床精神医学講座5, 神経症性障害・ストレス関連障害, 中山書店, 東京, pp178-184
 
17) 竹内龍雄:パニック障害 (追補改訂版) . 新興医学, 東京, pp33-35, 2000
 
18) 竹内龍雄:パニック障害 (追補改訂版) . 新興医学, 東京, pp108-113, 2000
 
19) World Health Organlzatlon:The ICD-IO CIassification of Mental and Behavioural Disorders:Clinical descriptions and diagnostic guidelines. World Health Organization, 1992 (融道男, 中根允文, 小見山丈 監訳:ICD-10精神および行動の障害-臨床記述と診断ガイドライン-. 医学書院, 東京, 1994)
 
20) World Health Organization:The ICD-IO CIassification of Mental and Behavioural Disorders:Diagnostic criteria for research. World Health Organization, 1993 (中根允文, 岡崎祐士, 藤原妙子訳:ICD-10 精神および行動の障害-DCR研究用診断基準-. 医学書院, 東京, 1994, pp109-110
 

Part 3/Strategy

P.66 掲載の参考文献
1) 穐吉條太郎:【精神疾患100の仮説】パニック障害, 全般性不安障害の仮説, 社会心理モデル, 認知機能異常モデル. こころの臨床ア・ラ・カルト増刊号, 170-173, 1998
 
2) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. (DSM-III). American Psychiatric Association Press, Washington D.C., 1980
 
3) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). American Psychiatric Association Press, Washington D.C., 1994
 
4) American Psychiatric Association:Practice Guideline for the Treatment of Patients with Panic disorder, American Psychiatric Association Press, Washington D.C., 1998
 
5) Aoki Y, Fujihara S, Kitamura T:Panic attacks and panic disorder in Japanese non-patient population:epidemiology and psychosocial correlates. J Affect Disord 32:51-59, 1994
PubMed
6) Azhar MZ:Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan--implications for management by family doctors. Med J Malaysia 55:402-408, 2000
PubMed
7) Ballenger JC, Lydiard RB:Panic Disorder:Results of a Patient Survey. Human Psychopharmacol 12:S27-33, 1997
 
8) Ballenger JC:Selective serotonin reuptake inhibitors (SSRIs) in panic disorder. Panic Disorder Clinical Diagnosis, Management and Mechanisms, ed. by Nutt DJ, Ballenger JC, Lepine JP, Martin, London, pp159-178, 1999
 
9) de Beurs E, van Balkom AJ, Van Dyck R et al:Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia:a 2-year naturalistic follow-up. Acta Psychiatr Scan 99:59-67, 1999
 
10) Dewan MJ, Anand VS:Evaluating thetolerability of the newer antidepressants. J Nerv Ment Dis 187:96-101, 1999
PubMed
11) Eaton WW, Kessler RC, Wittchen HU et al:Panic and panic disorder in the United States. Am J Psychiatry 151:413-420, 1994
PubMed
12) Gorman JM, Liebowitz MR, Fyer AJ et al:A neuroanatomical hypothesis for panic disorder. Am J Psychiatry 146:148-161, 1989
PubMed
13) Gorman JM, Kent JM, Sullivan GM et al:Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157:93-505, 2000
 
14) Hollifield M, Katon W, Skipper B et al:Panic disorder and quality of life:variables predictive of functional impairment. Am J Psychiatry 154:766-772, 1997
PubMed
15) Katschnig H, Amering M, Stolk JM et al:Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull 32:149-155, 1996
 
16) Katschnig H:Anxiety neurosis, panic disorder or what? Panic Disorder Clinical Diagnosis, Management and Mechanisms, ed. by Nutt DJ, Ballenger JC, Lepine Jp, Martin, London, pp1-8, 1999
 
17) 越野好文, 村田哲人, 大森昭夫ほか:パニック障害患者のQOL. 精神経誌 96 (12):1118, 1994
 
18) Noyes Jr R, Hoehn-Saric R:Panic disorder and agoraphobia. The Anxiety Disorders, Cambridge University Press, Cambridge, pp86-157, 1998
 
19) Nutt DJ, Ballenger JC, Lepine Jp:Overview and future prospects. Panic Disorder Clinical Diagnosis, Management and Mechanisms, ed. by Nutt DJ, Ballenger JC, Lepine Jp, Martin, London, pp221-228, 1999
 
20) Roy Byrne PP, Cowley DS:Course and outcome in panic disorder:a review of recent follow-up studies. Anxiety 1:150-160, 1995
 
21) Satoh K, Fujii I:Current views on panic disorder and its management in Japan:a national survey. Jpn J Psychiatry Neurol 46:45-53, 1992
PubMed
22) 塩入俊樹, 村下 淳, 加藤忠史ほか:恐慌性障害の症例研究. Panic Grand Round'95, パニック障害研究最前線, 藤井 薫ほか編著, ライフサイエンス社, 東京, pp 1-8, 1996
 
23) 塩入俊樹:パニック障害の臨床-現状と将来-最新心身医学, 河野友信, 山岡昌幸, 石川俊男ほか編, 三輪書店, 東京, pp221-232, 2000
 
24) Weissman MM, Biand RC, Canino GJ et al:The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54:305-309, 1997
 
P.77 掲載の参考文献
1) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. American Psychiatric Association, Washington DC, 1980
 
2) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington DC, 1994. (DSM-IV精神疾患の診断・統計マニュアル. 高橋三郎, 大野 裕, 染矢俊幸訳, 医学書院, 東京, p834, 1996)
 
3) American Psychiatric Association:Practice Guideline for the Treatment of Patients with Panic Disorder. American Psychiatric Association, Washington DC, 1998. (米国精神医学会治療ガイドライン, パニック障害. 日本精神神経学会監訳, 医学書院, 東京, p116, 1999)
 
4) 稲田泰之, 米田 博:パニック障害の長期治療計画. 臨床精神薬理3:11-16, 2000
 
5) Katschnig H, Amering M, Stolk JM et al:Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry 167:487-494, 1995
PubMed
6) 越野好文:パニック障害の治療. 北陸神経精神医学誌 9:1-5, 1995
 
7) 越野好文:日常診療に必要な応急処置-不安発作 (パニック発作) . Medical Practice 15 (増刊号):157-158, 1998
 
8) McGlynn TJ, Metcalf HL (eds):Diagnosis and Treatment of Anxiety Disorders:A Physician's Handbook. 2nd ed. American Psychiatric Press, Washington DC, 1991 (不安障害臨床ハンドブック. 越野好文訳, 金剛出版, 東京, p211, 1994)
 
9) Michelson D, Lydiard RB, Pollack MH et al:Outcome assessment and clinical improvement in panic disorder:evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 155:1570-1577, 1998
 
10) Pelissolo A, Lepine Jp:Treatment of difficult panic patients. Difficult Clinical Probiems in Psychiatry ed. by Lader M, Naber D, Martin Dunitz, London, pp77-96, 1999
 
11) 坂本暢典:Panic disorderとうつ病のcomorbidity(合併)に対する治療的対応について. 精神科治療学 8:649-656, 1993
 
12) 佐々木高伸:パニックディスオーダーに他の治療はないのか. パニックディスオーダー. 上島国利編, 国際医書出版, 東京, 1996, pp78-88
 
13) Schatzberg AF, Ballenger JC:Decisions for the clinician in the treatment of panic disorder:when to treat, which treatment to use, and how long to treat. J Clin Psychiatry 52 (Suppl):26-31, 1991
 
14) Sheehan D:パニック障害とその治療. パニック障害研究最前線. 貝谷久宣編, 日本評論社, 東京, pp11-54, 2000
 
15) 塩入俊樹, 染矢俊幸:治療が困難なパニック障害の薬物療法. 臨床精神薬理 3:463-471, 2000
 
16) 竹内龍雄:パニック障害におけるBZの位置づけ-alprazolamを中心に-. 臨床精神薬理 3:1175-1188, 2000
 
17) 竹内龍雄, 花澤 寿:パニック障害の治療. 精神科治療学 8:633-639, 1993
 
18) 筒井末春, 小山 司, 奥瀬 哲ほか:選択的セロトニン再取り込み阻害薬塩酸パロキセチンのパニック障害に対する臨床評価-第III相二重盲検群問比較試験-. 薬理と治療 28 (増 1):S295-S314, 2000
 
19) 筒井末春, 長田洋文, 村中一文ほか:選択的セロトニン再取り込み阻害薬塩酸セルトラリンの恐慌性障害に対する臨床評価-プラセボを対照とした二重盲検比較試験による用量ならびに有効性・安全性の検討-. 神経精神薬理 19:639-657, 1997
 
20) Weekes C:Simple, effective treatment of agoraphobia. Am J Psychother 32:357-369, 1978
PubMed
P.87 掲載の参考文献
1) Klein DF, Fink M:Psychiatric reaction patterns to imipramine. Am J Psychiatric 119:432-438, 1962
 
2) American Psychiatric Association:Practice guideline for the treatment of patients with panic disorder. 1998 (米国精神医学会治療ガイドライン パニック障害. 監訳 日本精神神経学会医学書院, 東京, 1999)
 
3) den Boer JA:Pharmacotherapy of panic disorder:differential efficacy from a clinical viewpoint. J Clin Psychiatry 59 (Suppl 8):30-36, 1998
 
4) Hoehn-Saric R, McLeod DR, Hipsley PA:Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 3:321-326, 1993
PubMed
5) Black DW, Wesner R, Bowers W et al:A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50:44-50, 1993
 
6) Oehrberg S, Christiansen PE, Behnke K et al:Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167:374-379, 1995
PubMed
7) Lecrubier Y, Bakker A, Dunbar G et al:A comparison of paroxetine, ciomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95:145-152, 1997
 
8) Lecrubier Y, Judge R:Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95:153-160, 1997
 
9) Ballenger JC, Wheadon DE, Steiner M et al:Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155:36-42, 1998
PubMed
10)Wade AG, Lepola U, Koponen HJ et al:The effect of citalopram in panic disorder. Br J Psychiatry 170:549-553, 1997
PubMed
11) Boyer W:Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks:a meta-analysis. Int Clin Psychopharmacol 10:45-49, 1995
PubMed
12) 筒井末春, 小山 司, 奥瀬 哲ほか:選択的セロトニン再取り込み阻害薬塩酸パロキセチンのパニック障害に対する臨床評価-第III相二重盲検群間比較試験-. 薬理と治療28 (Suppl), 2000
 
13) Ballenger JC, Davidson JR, Lecrubier Y et al:Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59 (Suppl 8):47-54, 1998
 
14) Louie AK, Lewis TB, Lannon RA:Use of lowdose fluoxetine in major depression and panic disorder. J Clin Psychiatry 54:435-438, 1993
PubMed
15) Burnham et al:Relapse prevention in panic disorder. ACNP, 1995 (文献16) より)
 
16) David V Sheehan:パニック障害とその治療パニック障害研究最前線. (貝谷久宣, 不安・抑うつ臨床研究会編). 日本評論社, 東京, 2000, pp11-54
 
17) Simon GE, VonKorff M, Wagner EH et al:Patterns of antidepressant use in community Practice. Gen Hosp Psychiatry 15:399-408, 1993
PubMed
18) Rickels K, Schweizer E, Weiss S et al:Maintenance drug treatment for panic disorder, II. Short-and long-term outcome after drug taper. Arch Gen Psychiatry 50:61-68, 1993
 
19) Mavissakalian M, Perel JM:Protective effects of lmlpramlne malntenance treatment ln pamc disorder with agoraphobia. Am J Psychiatry 149:1053-1057, 1992
 
20) Pollack MH, Worthington JJ 3rd, Otto MW et al:Venlafaxine for panic disorder:results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32:667-670, 1996
PubMed
21) Priest RG, Gimbrett R, Roberts M et al:Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatr Scand (Suppl);386:40-43, 1995
PubMed
22)上島国利, 野崎伸次:パニック・ディスオーダーの薬物療法. 精神医学レビューNo. 3パニック・ディスオーダー. 高橋 徹編. ライフサイエンス, 東京, 1992, p66-82
 
23) Ballenger JC, Burrows GD, DuPont RL Jr et al:Alprazolam in panic disorder and agoraphobia:results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 45:413-422, 1988
PubMed
24) Rickels K, Schweizer E:Panic disorder:long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 18 (Suppl 2):S12-S18, 1998
 
25) Lydiard RB, Lesser IM, Ballenger JC et al:A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 12:96-103, 1992
PubMed
26) Woodman CL, Noyes R Jr:Panic disorder:treatment with valproate. J Clin Psychiatry 55:134-136, 1994
PubMed
27) Pande AC, Pollack MH, Crockatt J et al:Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467-471, 2000
PubMed
28) Saeed SA, Bruce TJ:Panic disorder:effective treatment options. Am Fam Physician 57 2405-2412, 1998
PubMed
29) Ballenger JC, Lydiard RB, Turner SM:Panic disorder and agoraphobia. In:Gabbard GO, ed. Treatments of psychiatric disorders. Vol 2. Washington, D.C.:American Psychiatric Press, 1995.
 
30) DeMartinis NA, Schweizer E, Rickels K:An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 57:245-248, 1996
PubMed
31) Geracioti TD Jr:Venlafaxine treatment of panicdisorder:a case series. J Clin psychiatry 56:408-410, 1995
 
32) Benjamin J, Levine J, Fux M et al:Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 152:1084-1086, 1995
PubMed
33) Charney DS, Woods SW, Goodman WK et al:Drug treatment of panic disorder:the comparative efflcacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 47:580-586, 1986
PubMed
34) Mavissakalian M, Perel J, Bowler K et al:Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 144:785-787, 1987
PubMed
35) Klein E, Uhde TW:Controlled study of verapamil for treatment of panic disorder. Am J Psychiatry 145:431-434, 1988
PubMed
36) Keck PE Jr, Taylor VE, Tugrul KC et al:Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 33:542-546, 1993
PubMed
37) Lecrubier Y:The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry 59(Suppl 8):11-14, 1998
 
38) Jobson KO, Davidson JR, Lydiard RB et al:Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull 31:483-485, 1995
PubMed
39) 古賀聖名子, 中山和彦, 和久津直美:不安障害治療のガイドラインとアルゴリズム-Panic Disorder, OCD, PTSDに焦点を置いて-臨床精神薬理 4:471-477, 2001
 
40) Roy-Byrne PP, Stein MB, Russo J et al:Panic disorder in the primary care setting:comorbidity, disability, service utilization, and treatment. J Clin Psychiatry 60:492-499, 1999
PubMed
41) American Psychiatric Association:Diagnostic and Statistical manual of Mental Disorders, 4th edition. APA, Washington DC, 1994
 
42) Pecknold J, Luthe L, Munjack D et al:A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 14:314-321, 1994
PubMed
43) Beauclair L, Fontaine R, Annable L et al:Clonazepam hl the treatment of panic disorder:a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 14:111-118, 1994
 
44) Ballenger JC, Davidson JR, Lecrubier Y et al:Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59 (Suppl 17):54-60, 1998
 
45) Uhlenhuth EH, Balter MB, Ban TA et al:Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997. Eur Neuropsychopharmacol 9 (Suppl 6):S393-S398,1999
 
46) 黒木俊秀, 田代信維:不安障害治療薬の基本間題. 臨床精神薬理 4:57-64, 2001
 
47) 尾鷲登志美, 上島国利:パニック障害の薬物療法. 心療内科 5:147-152, 2001
 
P.93 掲載の参考文献
1) Moeller HJ:Effectiveness and safety of benzo-diazepines. J Clin Psychopharmacol 19 (Suppl 2):S2-S11, 1999
 
2) Rickels K, DeMartinis N, Rynn M et al:Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 19 (Suppl 2):S12-S16, 1999
 
3) 大坪天平, 上島国利:抗不安薬の薬物依存, 筒井末春編, 医薬ジャーナル社, 大阪, 1997, pp119-130
 
4) Dilsaver SC, Kronfol Z, Sackellares JC et al:Antidepressant withdrawal syndrome:evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 3:157-164, 1983
PubMed
5) Schatzberg AF, Haddad CP, Kaplan EM et al:Serotonin reuptake inhibitor discontinuation syn-drome:Ahypothetical definition. J Clin Psychiatry 58 (Suppl 7):5-10, 1997
 
6) Schatzberg AE Haddad CP, Kaplan EM et al:Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Psychiatry 58 (Suppl 7):23-27, 1997
 
P.99 掲載の参考文献
1) 坂上紀幸, 清水宗夫:臨床精神医学講座14, 抗うつ薬の副作用とその対策, 松下正明編, 中山書店, 東京, pp151-162, 1999
 
2) 下田和孝:臨床精神医学講座14, 抗不安薬の副作用, 松下正明編, 中山書店, 東京, pp233-238, 1999
 
3) Sternbach H:The serotonin syndrome. Am J Psychiatry 148:705-713, 1991
PubMed
4) Mills KC:Serotonin syndrome. Am fam Psysician 52:1475-1482, 1995
 
5) 渡辺昌祐:抗不安薬の選び方と使い方, 抗不安薬の副作用, 金原出版, 東京, pp197-220, 1994
 
6) 渡辺昌祐, 横山茂生:抗うつ薬の選び方と使い方, 抗うつ薬の副作用とその対策, 新興医学出版, 東京, pp189-216, 1993
 
7) 永田昌弘, 吉村匡史, 宮田恵美子ほか:関西医科大学附属病院におけるFluvoxamineの処方動向, 強迫性障害の研究 (2), 上島国利, 大森哲郎編, 星和書店, 東京, pp 1-6, 2001
 
8) Philipp M, Tiller JWG, Baier D et al:Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRI) on sexual function in depressed adults. Eur Neuropsychopharmacol 1O:305-314, 2000
 
P.104 掲載の参考文献
1) Kaplan HI, Sadock BJ, Grebb JA, eds:Comprehensive textbook of psychiatry. Baltimore:Williams & Wilkins, 1994
 
2) Nelson DR, Koymans L, Kamataki T et at:P450 superfamily:update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42, 1996
PubMed
3) Eichelbaum M, Spannbrucker N, Steincke B et al:Defective N-oxidation of sparteine in man:a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183-187, 1979
 
4) Mahgoub A, Idle JR, Dring LG et al:Poly-morphic hydroxylation of Debrisoquine in man. Lancet 2:584-586, 1977
 
5) Tucker GT, Silas JH, Iyun AO et al:Polymorphic hydroxylation of debrisoquine. Lancet 2:718, 1977
PubMed
6) Bertilsson L, Lou YQ, Du YL et al:Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397, 1992
PubMed
7) Gaedigk A, Blum M, Gaedigk R et al:Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48:943-950, 1991
PubMed
8) Gough AC, Miles JS, Spurr NK et al:Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347:773-776, 1990
PubMed
9) Heim M, Meyer UA:Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532, 1990
PubMed
10) Johansson I, Oscarson M, Yue QY et al:Genetic analysis of the Chinese cytochrome P4502D locus:characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459, 1994
PubMed
11) Kagimoto M, Heim M, Kagimoto K et al:Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214, 1990
 
12) Yokota H, Tamura S, Furuya H et al:Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in-vivo rates of sparteine metabolism. Pharmacogenetics 3:256-263, 1993
 
13) Eiermann B, Engel G, Johansson I et al:The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 44:439-446, 1997
 
14) Jerling M, Merle Y, Mentre F et al:Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 44:447-453, 1997
PubMed
15) Ketter TA, Flockhart DA, Post RM et al:The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15:387-398, 1995
PubMed
16) Nielsen KK, Brosen K, Hansen MG et al:Single-dose kinetics of clomipramine:relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 55:518-527, 1994
 
17) Horai Y, Nakano M, Ishizaki T et al:Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects:Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207, 1989
PubMed
18) Jurima M, Inaba T, Kadar D et at:Genetic polymorphism of mephenytoin p (4')-hydroxylation:difference between Orientals and Caucasians. Br J Clin Pharmacol 19:483-487, 1985
 
19) Nakamura K, Goto F, Ray WA et al:Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402-408, 1985
PubMed
20) Sohn DR, Kusaka M, Ishizaki T et al:Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 52:160-169, 1992
 
21) Alvan G, Bechtei P, Iselius L et al:Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533-537, 1990
 
22) de Morais SM, Wilkinson GR, Blaisdell J et al:The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422, 1994
PubMed
23) de Morais SM, wilkinson GR, Blaisdell J et al:Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598, 1994
PubMed
24) Gonzalez FJ:Human cytochromes P450:problems and prospects. Trends Pharmacol Sci 13:346-352, 1992
PubMed
25) Shimada T, Yamazaki H, Mimura M et al:Interindividual variations in human liver cytochrome P-450 enzymes involv ed in the oxidation of drugs, carcinogens and toxic chemicals:studies with liver microsomes of 30 Japanese and 30 Caucasians. Pharmacol Exp Ther 270:414-423, 1994
 
26) Kaminsky LS, Fasco MJ:Small intestinal cytochrome P450. Crit Rev Toxicol 21:407-422, 1991
PubMed
27) Kolars JC, Schmeidlin-Ren P, Schuetz JD et al:Identification of rifampicin-inducible P450III A (CYP3A4) in human small bowel enterocytes. J Clin lnvest 90:1871-1878, 1991
 
28) Lown KS, Thummel KE, Benedict PE et al:Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955, 1995
 
29) Kronbach T, Mathys D, Umeno M et al:Oxidation of midazolam and triazolam by human liver cytochrome P450III A4. Mol Pharmacol 36:89-96, 1989
 
30) Reilly PE, Thompson DA, Mason SR et al:Cytochrome P450IIIA enzymes in rat liver microsomes:involvement in C3-hydroxylation of diazepam and nordazepam but not Ndealkylation of diazepam and temazepam. Mol Pharmacol 37:767-774, 1990
 
31) Yasui N, Otani K, Kaneko S et al:Akinetic and dynamic study of oral alprazolam with and without erythromycin in humans:in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 59:514-519, 1996
 
32) Phillips Jp, Antal EJ, Smith RB:A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 6:297-299, 1986
PubMed
33) Olkkola KT, Aranko K, Luurila H et al:A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305, 1993
PubMed
34) OLkkola KT, Backman JT, Neuvonen PJ:Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485, 1994
PubMed
35) Varhe A, Olkkola KT, Neuvonen PJ:Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607, 1994
PubMed
36) Lemoine A, Gautier JC, Azoulay D et al:Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 43:827-832, 1993
PubMed
37) Jerling M, Bertilsson L, Sjoqvist F:The use of therapeutic drug monitoring data to document kinetic drug interactions:an example with amitriptyline and nortriptyline. Ther Drug Monit 16:1-12, 1994
PubMed
38) Otani K, Nordin C, Bertilsson L:No interaction of diazepam on amitriptyline disposition in depressed patients. Ther Drug Monit 9:120-122, 1987
PubMed
39) Shimoda K, Minowada T, Noguchi T et al:Interindividual variations of desmethylation and hydroxylation of clomipramine in an Oriental psychiatric population. J Clin Psychopharmacol 13:181-188, 1993
 
40) Shimoda K, Noguchi T, Morita S et al:Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. J Clin Psychopharmacol 15:175-181, 1995
 
41) Silverman G, Braithwaite RA:Benzodiazepines and tricyclic antidepressant plasma levels. Br Med J 2:18-20, 1973
 
42) von Moltke LL, Greenblatt DJ, Court MH et al:Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine:comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131, 1995
PubMed
43) Lasher TA, Fleishaker JC, Steenwyk RC et al:Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. ,Psychopharmacology 104:323-327, 1991
PubMed
44) Greenblatt DJ, Preskorn SH, Cotreau MM et al:Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 52:479-486, 1992
 
45) 鈴木雄太郎, 塩入俊樹, 村竹辰之ほか:Alprazolamおよびetizolam血中濃度に対するfluvoxamine併用の影響:CYP2C19変異アレル数と交互作用について. 精神薬療研究年報 33:199-204, 2001
 
46) Bergstrom RF, Peyton AL, Lemberger L:Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51:239-248, 1992
PubMed
47) Brosen K, Hansen JG, Nielsen KK et al:Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44:349-355, 1993
 
48) Preskorn SH, Alderman J, Chung M et al:Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14:90-98, 1994
 
49) Spina E, Pollicino AM, Avenoso A et al:Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res 13:167-171, 1993
PubMed
50) Spina E, Pollicino AM, Avenoso A et al:Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243-246, 1993
PubMed
51) Hater S, Wetzel H, Hammes E et al:Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 110:302-308, 1993
 
52) Maskall DD, Lam RW:Increased plasma concentration of imipramine following augmentation with fluvoxamine:letter. Am J Psychiatry 150:1566, 1993
PubMed
53) Spino E, Campo GM, Avenoso A et al:Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 14:194-196, 1992
 
54) Vandel S, Bertschy G, Baumann P et al:Fluvoxamine and fluoxetine:interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31:347-353, 1995
PubMed
55) Hartter S, Arand M, Oesch F et al:Noncompetitive inhibition of clomipramine N-demethylation by fluvoxamine. Psychopharmacology 117:149-153, 1995
PubMed
56) Robinson RF, Nahata MC, Olshefski RS:Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann Pharmacother 34:1406-1409, 2000
PubMed
57) Dorsey ST, Biblo LA:Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 18:227-229, 2000
PubMed
58) Newberry DL, Bass SN, Mbanefo CO:A fluconazole/amitriptyline drug interaction in three male adults. Clin lnfect Dis 24:270-271, 1997
PubMed
59) Kruger MB, Dahl AA:The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Pyschiatry Clin Neurosci 249:(Suppl 1) S19-S24, 1999
 
60) Tiller JW, Bouwer C, Behnke K:Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249:(Suppl l) S7-S10, 1999
 
61) Gram LF, Guentert TW, Grange S et al:Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2:a panel study. Clin Pharmacol Ther 57:670-677, 1995
 
62) Yu KS, Yim DS, Cho JY et al:Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 69:266-273, 2001
 
63) Crewe HK, Lennard MS, Tucker GT et al:The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265, 1992
PubMed
P.116 掲載の参考文献
1) American Psychiatric Association:Practice guideline for the treatment of patients with Panic Disorders. Washington D.C., American Psychiatric Association, 1998
 
2) Bandura A:Self-efficacy in changing society. Cambridge:Cambridge University Press, 1995
 
3) Barlow DH, Cerny JA:Psychological treatment of panic. New York:Guilford, 1990
 
4) National Institutes of Health:Treatment of Panic Disorder. NIH Consensus Development Conference Consensus Statement 9:25-27, 1991
 
5) 坂野雄二:パニック障害の認知行動療法. 貝谷 久宣・不安抑うつ臨床研究会 (編) 「パニック障害」, 日本評論社, 1998
 
6) 坂野雄二, 貝谷久宣:パニック障害の行動療法. 精神療法 25:314-320, 1999
 
7) 竹内龍雄:パニック障害の診断・治療の実際. 精神医学レビュー3:46-53, 1992
 
8) 竹内龍雄:突然, 胸がどきどきして息ができない. NHK, 2000
 
P.127 掲載の参考文献
1) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, IVth ed, APA, Washington DC, 1994 (高橋三郎, 大野 裕, 染矢俊幸訳:DSM-IV精神疾患の診断・統計マニュアル. 医学書院東京, 1996, pp125)
 
2) American Psychiatric Association:Practice Guideline for the Treatment of Patients with Panic Disorders. APA, Washington DC, 1998 (日本精神神経学会監訳, 米国精神医学会治療ガイドライン, パニック障害. 医学書院, 東京, 1999)
 
3) Beck AT:Cognitive therapy and the Emotional disorders. International University Press, 1976 (大野 裕訳, 認知療法. 岩崎学術出版, 東京, 1990)
 
4) Beck AT, Emery G:Anxiety Disorders and Phobias. A Division of Harper Collins Publishers, 1985
 
5) Bienvenu OJ, Nestadt G, Samuels JF et al:Phobic, panic, and major depressive disorders and the five-factor model of personality. J Nerv Ment Dis 189:154-161, 2001
PubMed
6) Busch FN, Milrod BL, Singer MB:Theory and technique in psychodynamic treatment of panic disorder. J Psychother Pract Res 8:234-242, 1999
PubMed
7) Freeman A:The Practice of Cognitive Therapy. (遊佐安一郎, 認知療法人門. 星和書店, 東京, 1989)
 
8) Freud S:Uber die Berechtigung, von der Neurasthenie einen bestimmten Sympotomen Komplex Als"Angstneurose"abzutrennen. 1895 (「不安神経症」という特定症状群を神経衰弱から分類する理由について. フロイド選集10巻, 本教文社, 東京, 1995, pp 1)
 
9) Horesh N, Amir M, Kedem P et al:Life events in childhood, adolescence and adulthood and the relationship to panic disorder. Acta Psychiatr Scand 96:373-378, 1997
PubMed
10) Horney K:The Neurotic Personality of our Time. WW Norton & Company Inc., New York, 1937 (我妻洋訳, 現代の神経症的人格. 誠信書房, 東京, 1973, pp66-87)
 
11) Klein DF:Delineation of Two Drug-Responsive Anxiety Syndromes. Psycho Pharmacologia 5:397-408, 1964
 
12) 森田正馬:神経質の本態及療法. 森田正馬全集第2巻, 白揚社, 東京, 1974, pp279-393
 
13) 中村 敬:森田療法における治療過程の検討-対人行動の分析を通じて-. 慈恵医大誌104:821-841, 1989
 
14) 中村 敬, 三宅 永:神経症に対する薬物療法の実際. 精神科治療学13:709-714, 1998
 
15) 西園昌久:類型. 下坂幸三, 諏訪 望, 西園昌久編, 現代精神医学大系6A, 神経症と心因反応I, 中山書店, 東京, 1978, pp181-236
 
16) 野村総一郎:エソロジー的に診る不安障害. こころの臨床アラカルト 18:454-457, 1999
 
17) Shear MK:Psychotherapy for panic disorder. Psychiatr Q 66:321-328, 1995
PubMed
18) Shear MK, Weiner K:Psychotherapy for panic disorder. J Clin Psychiatry 58 (Suppl 2):38-43, 1997
 
19) 立松一徳:パニック障害. 心身医療 9:1515-1518,1997
 
20) 立松一徳:乗り物恐怖を主訴とするパニックディスオーダー.黒澤 尚,北西憲二, 大野 裕編, 精神科プラクティス第3巻神経症とその周辺. 星和書店, 東京, 1999, pp93-102
 
21) 豊原利樹:森田神経質の性格特性および入院森田療法の治療効果について. 森田療法の研究, 森温理, 北西憲二編, 金剛出版, 東京, 1989, pp69-89
 
22) 山上敏子:行動理論・学習理論. 下坂幸三, 諏訪望, 西園昌久編, 現代精神医学大系6A, 神経症と心因反応I,中山書店, 東京, 1978, pp89-108
 
23) Zeitlin SB, McNally RJ:Alexithymia and anxiety sensitivity in panic disorder and obsessive-compulsive disorder. Am J Psychiatry 150:658-660, 1993
PubMed

Part 4/Practice

P.139 掲載の参考文献
1) Ballenger JC:Selective serotonin reuptake inhibitors (SSRI) in panic disorder. Chap. II. In Panic Disorder:Clinical Diagnosis, Management and Mechanisms (Nutt et al Ed.) . Martin Dunitz, London, 1999 (日本語訳:久保木富房, 井上雄一, 日本評論社 pp201-227)
 
2) Ballenger JC, Wheadon DE, Steiner M et al:Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155:36-42, 1998
PubMed
3) Black DW, Wesner R, Bowers W et al:A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50:44-50, 1993
 
4) de Jonghe F, Swinkels J:Selective serotonin reuptake inhibitors. Relevance of differences in their pharmacological and clinical profiles. CNS Drugs (6):452-467, 1997
 
5) Goddard AW, Brouette T, Almai A et al:Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatiy 58:681-686, 2001
 
6) Hoehn-Saric R, McLeod DR, Hipsley PA:Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 13:321-326, 1993
PubMed
7) 越野好文:臨床精神医学講座 第5巻 神経症性障害・ストレス関連障害. II. 診断と治療 B. パニック障害 9. 治療 a. 薬物療法. 総集編, 松下正明/責任編集, 越野好文, 田代信維. 中山書店, 東京, 1997, pp248-261
 
8) Laufer N, Weizman A:Other drug treatments and augmentation therapies for panic disorder. Chap.12. In Panic Disorder:Clinical Diagnosis, Management and Mechanisms (Nutt et al Ed.) . Martin Dunitz, London, 1999 (日本語訳:久保木富房, 井上雄一, 日本評論社, pp231-256)
 
9) Oehrberg S, Christiansen PE, Behnke K et al:Paroxetine in the treatment of panic disorder. randomised, double-blind, placebo-controlled study. Br J Psychiatry 167:374-379, 1995
PubMed
10) Pohl RB, Wolkow RM, Clary CM:Sertraline in the treatment of panic disorder:adouble-blind multicenter trial Am J Psychiatry 155:1189-1195, 1998
 
11) Marks I, O:Sullivan G:Drugs and psychological treatments for agoraphobia/panic and obsessive-compulsive disorders:a review. Br J Psychiatry 153:650-658, 1988
PubMed
12) Rosenberg R:Treatment of panic disorder with tricyclics and MAOIs. Chap. 9. In Panic Disorder:Clinical Diagnosis, Management and Mechanisms (Nutt et al Ed.) . Martin Dunitz, London, 1999 (日本語訳:久保木富房, 井上雄一, 日本評論社, pp161-183)
 
13) 佐藤啓二:臨床精神医学講座 第5巻 神経症性障害・ストレス関連障害. II. 診断と治療 B. パニック障害 9. 治療 b. 心理療法 (認知療法・行動療法・精神療法) . 総集編, 松下正明/責任編集, 越野好文, 田代信維. 中山書店東京, 1997, pp262-272
 
14) 佐藤啓二, 高橋徹 (編著) パニック障害の心理的治療法-理論と実践-(平成7年度精神神経学会サテライトワークショップ講演録), ブレーン出版, 東. 京, 1996
 
15) 佐藤啓二:パニック障害を合併する気分障害例に対するfluvoxamineの臨床効果. 「SSRI最新情報」 (村崎. 光邦, 上島国利, 樋口輝彦編) 協和企画, 2000, pp53-57.
 
16) 佐藤啓二:私の治療法, パニック障害の治療. 精神科治療学16:189-192, 2001
 
17) WPA:Panic Anxiety and its Treatment. WPA Presidentional Program Task Force, AP press, 1993/日本語訳:パニック性不安とその治療 (中根允文, 佐藤啓二監訳, 先端医学社, 1995)
 
P.145 掲載の参考文献
1) Ballenger JC, Lydiard RB, Turnaer SM:Panic disorder and agoraphobia. Treatment of psychiatric disorders. (ed. by Gobbard GO) . American Psychiatric Press, Washington DC, 1995
 
2) Ballenger JC:Panic disorder in the medical setting. J Clin Psychiatry 58 (Suppl 2):13-17, 1997
 
3) Barlow DH:Cognitive-behavioral therapy for panic disorder:current status. J Clin Psychiatry 58 (Suppl 2):32-36, 1997
 
4) Davidson JR:Use of benzodiazepines in panic disorder. J Clin Psychiatry 58 (Suppl 2) 26-28, 1997
 
5) Masand PS, Gupta S:Selective serotonin reuptake-inhibitors:an update. Harw Rev Ps:ychiatry 7:69-84, 1999
 
6) Sheehan DV, Harnett-Sheehan K:The role of SSRIs in panic disorder. J Clin Psychiatry 57 (Suppl 10):51-58, 1996
 
P.152 掲載の参考文献
1) Markowitz JS, Weissman MM, Ouellette R et al:Quality of life in panic disorder. Arch Gen Psychiatry 46:984-992, 1989
PubMed
2) Pollack MH, Otto MW, Rosenbaum JF et al:Longitudinal course of panic disorder:findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry 51:12-16, 1990
PubMed
3) Wade SL, Monroe SM, Michelson LK:Chronic life stress and treatment outcome in agoraphobia with panic attacks. Am J Psychiatry 150:1491-1495, 1993
PubMed
4) Lecrubier Y, Judge R:Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatry Scand 95:153-160, 1997
 
5) Gorman J, Shear K Co-chair Work group on panic disorder:Practice guideline for the treatment of patients with panic disorder. American Psychiatric Association. Am J Psychiatry 155:(Suppl 5), 1998
 
6) Wiborg IM, Dahl AA:Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry 53:689-694, 1996
PubMed
7) Milrod B, Busch F, Leon AC et al:Open trial of psychodynamic psychotherapy for panic disorder:a pilot study. Am J Psychiatry 157:1878-1880, 2000
PubMed
8) Shear K, Weiner K:Psychotherapy for panic disorder. J Clin Psychiatry 58:(Suppl 2) 38-45, 1997
 
9) 守屋直樹, 生田憲正, 柴田恵理子ほか:神経症の精神分析的精神療法-どのような知識と技術が必要か-. 精神科治療学12:127-133, 1997
 
10) Milrod B, Busch F, Cooper A et al:Manual of panic-focused psychodynamic psychotherapy. American Psychiatric Press, Washington DC, 1997
 

Part 5/Care

P.163 掲載の参考文献
1) Work Group on Panic Disorder. American Psychiatric Association:Practice guideline for the treatment of patients with panic disorder. Amz J Psychiatry 155 (Suppl 5):1-34, 1998
 
2) Rapaport MH, Pollack M, Wolkow R et al:Is placebo response the same as drug response in panic disorder? Am J Psychiatry 157 1014-1016, 2000
PubMed
3) Hirschfeld RMA:Placebo response in the treatment of panic disorder. Bull Menninger Clin 60:76-86, 1996
 
4) American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text revision American Psychiatric Association Washington, DC, 2000
PubMed
5) Penninx BW, Beekman AT, Honig A et al:Depression and cardiac mortality:results from acommunity-based longitudinal study. Arch Ceit,Psychiatry 58:221-227, 2001
 
6) Cowley DS, Arana GW:The diagnostic utility of lactate sensitivity in panic disorder. Arch Gen Psychiatry 47:277-284, 1990
PubMed
7) Chambless DL, Caputo GC, Jasin SE et al:The Mobility Inventory for Agoraphobia. Behav Res her 23:35-44, 1985
 
8) Regier DA, Kaelber CT, Rae DS et al:Limitations of diagnostic criteria and assessment instruments for mental disorders. Implications for research and policy. Arch Gen Psychiatry 55:109-115, 1998
PubMed
9) Kessler RC, Borges G, Walters EE:Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 56:617-626, 1999
PubMed
P.173 掲載の参考文献
1) Noyes R Jr, Clancy J, Woodman C et al:Environmental factors related to the outcome of panic disorder. A seven-year follow-up study. J Nerv Ment Dis 181:529-538, 1993
 
2) 竹内龍雄, 林 竜介, 根本豊實ほか:パニック障害の病像・経過および転帰について-210例の症例検討から-. 精神経誌95:855-860, 1993
 
3) Cowley DS, Flick SN, Roy-Byme PP:Longterm course and outcome in panic disorder:a naturalistic follow-up study. Anxiety 2:13-21, 1996
 
4) 竹内龍雄:パニック障害の経過・予後. パニック障害, 竹内龍雄著, 振興医学出版社, 東京, pp67-77, 2000
 
5) Noyes R Jr, Reich J, Christiansen J et al:Outcome of panic disorder. Relationship to diagnostic subtypes and comorbidity. Arch Gen Psychiatry 47:809-818, 1990
PubMed
6) Liebowitz MR:Panic disorder as a chronic illness. J Clin Psychiatry 58 (Suppl 13):5-8, 1997
 
7) Keller MB, Hanks DL:Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 17:551-570, 1993
PubMed
8) Tyrer P, Seivewright N, Ferguson B et al:The general neurotic syndrome:acoaxial diagnosis of anxiety, depression and personality disorder. Acta Psychiatr Scand 85:201-206, 1992
 
9) Markowitz JS, Weissmann MM, Ouellette R et al:Quality of life in panic disorder. Arch Gen Psychiatry 46:984-992, 1989
 
10) Faravelli C, Pallanti S:Recent life events and panic disorder. Am J Psychiatry 146:622-626, 1989
PubMed
11) 古田真理子, 工藤貴代美, 山田久美子ほか:パニック障害における治療抵抗性の予測因子について. 精神医学41:79-83, 1999
 
12) Pollack MH, Rapaport MH, Clary CM et al:Sertraline treatment of panic disorder:response in patients at risk for poor outcome. J Clin Psychiatry 61:922-927, 2000
PubMed
13) Mennin DS, Heimberg RG:The impact of comorbid mood and personality disorders in the cognitive-behavioral treatment of panic disorder. Clin Psychol Rev 20:339-357, 2000
PubMed
14) 山田久美子, 穐吉條太郎, 藤井 薫ほか:パニック・ディスオーダーとcoping. 精神科治療学9:957-960, 1994
 
15) Pollack MH, Otto MW, Rosenbaum JF et al:Longitudinal course of panic disorder:findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry 51 (12, suppl A):12-16, 1990
 
16) Keller MB, Hanks DL:Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 17:551-570, 1993
PubMed
17) 坂本暢典:パニック障害精神疾患との共存. 臨床精神医学講座, 神経症性障害・ストレス関連障害, 田代信維, 越野好文編, 中山書店, 東京, pp238-247, 1997
 
18) Breier A, Chamey DS, Heninger GR:Major depression in patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:1129-1135, 1984
 
19) Lesser IM, Rubin RT, Pecknold JC et al:Secondary depression in panic disorder and agoraphobia.I. Frequency, severity, and response to treatment. Arch Gen Psychiatry 45:437-443, 1988
PubMed
20) Savino M, Perugi G, Simonini E et al:Affective comorbidity in panic disorder:is there a bipolar connection? Affect Disord 28:155-163, 1993
 
21) 竹内龍雄, 林竜介, 冨山學人ほか:不安神経症の慢性期病像について. 精神医学30:105-107, 1988
 
22) Kessler RC, Stang PE, Wittchen HU et al:Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 55:801-808, 1998
PubMed
23) Scheibe G, Albus M:Predictors of outcome in panic disorder:a 5-year prospective follow-up study. J Affect Disord 41:111-116, 1996
PubMed
24) Breier A Charney DS, Heninger GR:The diagnostic validity of anxiety disorders and their relationship to depressive illness. Am J Psychiatry 142:787-797, 1985
PubMed
25) Albus M, Scheibe G:Outcome of panic disorder with or without concomitant depression:A 2-year prospective follow-up study. Am J Psychiatry 150:1878-1880, 1993
 
26) Rief W, Trenkamp S, Auer C et al:Cognitive behavior therapy in panic disorder and comorbid major depression. A naturalistic study. Psychother Psychosom 69:70-78, 2000
PubMed
27) Grunhaus L, Harel Y, Krugler T et al:Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications. Clin Neuropharmacol 11:454-461, 1988
PubMed
28) Frank E, Shear MK, Rucci P et al:Influence of panic-agoraphobic spectnlm symptoms on treatment response in patients with recurrent major depression. Am J Psychiatry 157:1101-1107, 2000
PubMed
29) Goodwin R, Olfson M:Treatment of panic attack and risk of major depressive disorder in the community. Am J Psychiatry 158:1146-1148, 2001
PubMed
30) Johnson J, Weissman MM, Klerman GL:Panic disorder, comorbidity, and suicide attempts. Arch Gen Psychiatry 47:805-808, 1990
PubMed
31) Lepine Jp, Chignon JM, Teherani M:Suicide attempts in patients with panic disorder. A rch Gen Psychiatry 50:144-149, 1993
 
32) Beck AT, Steer RA, Sanderson WC et al:Panic disorder and suicidal ideation and behavior:discrepant findings in psychiatric outpatients. Am J Psychiatry 148:1195-1199, 1991
PubMed
33) Friedman S, Smith L, Fogel A:Suicidality in panic disorder:a comparison with schizophrenic, depressed, and other anxiety disorder outpatients. J Anxiety Disord 13:447-461, 1999
PubMed
34) Markowitz JS, Weissman MM, Ouellette R et al:Quality of life in panic disorder. Arch Gen Psychiatry 46:984-992, 1989
PubMed
35)Fava GA, Rafanelli C, Ottolini F et al:Psychological well-being and residual symptoms in remitted patients with panic disorder and agoraphobia. J Affect Disord 65:185-190, 2001
PubMed
36) 竹内龍雄, 林竜介, 池田政俊ほか:パニック障害患者のQuality of Life-WHOQOL-100を用いた調査から-. 日社精医誌6:149-158, 1998
 
37) Katemdahl DA, Realini Jp:Quality of life and panic-related work disability in subjects with infrequent panic and panic disorder. J Clin Psychiatry 58:153-158, 1997
 
38) Mavissakalian MR, Perel JM, Talbott-Green M et al:Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiatry 43:848-854, 1998
PubMed
39) Pohl RB, Wolkow RM, Clary CM:Sertraline in the treatment of panic disorder:adouble-blind multicenter trial. Am J Psychiatry 155:1189-1195, 1998
 
40) Pollack MH, Otto MW, Worthington JJ et at:Sertraline in the treatment of panic disorder:a flexible-dose multicenter trial. Arch Gen Psychiatry 55:1010-1016, 1998
 
41) Lecrubier Y, Judge R:Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95:153-160, 1997
 
42) Michelson D, Lydiard RB, Pollack MH et al:Outcome assessment and clinical improvement in panic disorder:evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 155:1570-1577, 1998
PubMed
43) Telch MJ, Schmidt NB, Jaimez TL et al:Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. J Consult Clin Psychol 63:23-830, 1995
 
44) Griez E, Schruers K:Experimental pathophysiology of panic. J Psychosom Res 45:493-503, 1998
 
45) Charney DS, Heninger GR, Jatlow PI:Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 42:233-243, 1985
PubMed
46) Bradwejn J, Koszycki DS, Shriqui C:Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48:603-610, 1991
 
47) Nutt DJ, Glue P, Lawson C et al:Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiary 47:917-925, 1990
 
48) 竹内龍雄:パニック障害疫学・経過・予後. 臨床精神医学講座経症性障害・ストレス関連障害, 田代信維, 越野好文編, 中山書店, 東京, pp178-184, 1997
 
49) Stuart GL, Treat TA, Wade WA:Effectiveness of an empirically based treatment for panic disorder delivered in a service clinic setting:1-year follow-up. J Consult Clin Psychol 68:506-512, 2000
 
50) Cowain T:Cognitive-behavioural therapy via videoconferencing to a rural area. Aust N Z J Psychiatry 35:62-64, 2001
PubMed
51) Wright J, Clum GA, Roodman A et al:Abibliotherapy approach to relapse prevention in individuals with panick attacks. J Anxiety Disord 14:483-499, 2000
 
52) 1to LM, de Araujo LA, Tess VL et al:Selfexposure therapy for panic disorder with agoraphobia:randomised controlled study of extemal v. interoceptive self-exposure. Br J Psychiatry 178:331-336, 2001
 
53) Starcevic V:Treatment goals for panic disorder. J Clin Psychopharmacol 18 (Suppl 2):S19-S26, 1998
 
54) Barlow DH, Gorman JM, Shear MK et al:Cognitive-behavioral therapy, imipramine, or their combination for panic disorder:Arandomized controlled trial. JAMA 283:2529-2536, 2000
 
55) Glass RM:Panic disorder--It's real and it:s treatable. JAMA 283:2573-2574, 2000
 
56) Biederman J, Faraone SV, Hirshfeld-Becker DR et al:Patterns of psychopathology and dysfunction in high-risk children of parents with panic disorder and major depression. Am J Psychiatry 158:49-57, 2001
PubMed
57) Rosenbaum JF, Biederman J, Hirshfeld-Becker DR et al:Acontrolled study of behavioral inhibition in children of parents with panic disorder and depression. Am J Psychiatry 157:2002-2010, 2000
 
P.180 掲載の参考文献
1) Aronson TA, Craig TJ:Cocaine precipitation of panic disorder. Am J Psychiatry 143:643-645, 1986
PubMed
2) Boulenger Jp, Uhde Tw, wolff EA 3rd et al:Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch Gen Psychiatry 41:1067-1071, 1984
PubMed
3) Cox BJ, Norton GR, Swinson RP et al:Substance abuse and panic-related anxiety:acritical review. Behav Res Ther 28:385-393, 1990
 
4) George DT, Nutt DJ, Dwyer BA et al:Alcoholism and panic disorder:is the comorbidity more than coincidence? Acta Psychiatr Scand 81:97-107, 1990
PubMed
5) Kaplan HI, Sadock BJ, Grebb JA編著 (井上令:, 四宮滋子監訳):カプラン臨床精神医学テキスト DSM-IV診断基準の臨床への展開, メディカル・サイエンス・インターナショナル, 東京, 1999
 
6) Kenardy J, Fried L, Kraemer HC et al:Psychlogical precursors of panic attacks. Br J Psychiatry 160:668-673, 1992
 
7) Kushner MG, Sher KJ, Beitman BD:The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 147:685-695, 1990
PubMed
8) Markowitz JS, Weissman MM, Ouellette R et al:Quality of life in panic disorder. Arch Gen Psychiatry 46:984-992, 1989
PubMed
9) Pallanti S, Mazzi D:MDMA (Ecstasy) precipi-tation of panic disorder. Biol Psychiatry 32:91-95, 1992
 
10) Rapee RM, Litwin EM, Barlow DH:Impact of life events on subjects with panic disorder and on comparison subjects. Am J Psychiatry 147:640-644, 1990
PubMed
11) Weissman MM:The hidden patient:unrecognized panic disorder. J Clin Psychiatry 51 (Suppl):5-8, 1990
 
12) Work Group on Panic Disorder. American Psychiatric Association:Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 155 (Suppl):1-34, 1998
 
P.186 掲載の参考文献
1) Swinyard EA:Patient compliance instruction. In:Goodman & Gilman's. The pharmacological basis of therapeutics, 6th ed. 1980, p1671
 
2) 堀岡正義:服薬指導の指針. 医学のあゆみ 127:751, 1983
 
3) 宗像恒次:コンプライアンスをめぐって. 日本保健医療行動科学会:205-210, 日本保健医療行動科学会, 年報 (1986年 Vol.1) 日本保健医療行動科学会編集「健康と病気の行動科学」メジカルフレンド出版
 
4) 石崎高志:コンプライアンスの問題. 日本臨床 50:52-60, 1992
Medical*Online
5) Sackett DL, Snow JC:The magnitude and measurement of compliance. In R. B. Haynes, D. W. Taylor and D. L. Sackett (eds.):Compliance in health care, Baltimore;Johns Hopkins University Press, 1979
 
6) Haynes, R. B. Introduction, In R. B. Haynes, D. W. Taylor and D. L. Sackett (eds.):Compliance in health care, Baltimore;Johns Hopkins University Press, 1979
 
7) Luntz G, Austin R:New stick test for P.A.S. in urine:Report on use of"Phenistix"and problems of long-term chemotherapy for tuberculosis. Br Med J 1:1679-1984, 1960
 
8) 中井吉英:服薬コンプライアンス. 今日の治療 5:209-217, 1997
 
9) Boyd JR, Convington TR, Stawaszek WF et al:Drug defaulting:Determination of compliance. (first of two parts) Am J Hosp Pharm 31:362-367, 1974
 
10) Moser M, Wood D:Management of hypertension;the problem of physician adherence. JAMA 235:2297, 1976
PubMed
11) Cartwright A:Sources and effects of stress in health careers. In C.G. Stone,F. Cohen, and N.E. Adler (eds.),:Health psychology, San Francisco:Jossey-Bass, 1979
 
12) Hayness RB, Sackett DL, Taylor DW et al:Manipulation of the therapeutic regimen to improve compliance;Conceptions and mis-conceptions. Clin Pharmacol Ther 22:125-130, 1977
 
13) Wandless I, Davie JW:Can drug compliance in the elderly be improved? Br Med J 1:359-361, 1977
PubMed
14) de Vries TPGM, Henning RH, Hogerzeil HV et al (津谷喜一郎ほか訳):P-drugマニュアルWHOのすすめる医薬品適正使用, 医学書院, 東京, 1998
 
15) Epstein RM:The patient-physician relationship. Fundamentals of Clinical Practice;A Textbook on the Patient, Doctor and Society, Mengel MB et al (ed), Plenum Press, New York, pp105-132, 1997
 
16) 大西基喜, 福井次矢:一般診療における医師-患者関係:松下正明ら編集, 臨床精神医学講座S7:総合診療における精神医学, 中山書店, 東京, pp134-145, 2000
 
17) 三浦貞則:薬物療法における倫理的側面, 患者への薬剤情報伝達をめぐる問題:松下正明ら編集, 臨床精神医学講座S12:精神医学・医療における倫理とインフォームド・コンセント, 中山書店, 東京, pp277-291, 2000
 
18) 天保英明:産業心身医学の実践 (4)-治療の立場から-心身医療10:63-67, 1998
 

書評

最近チェックした商品履歴

Loading...